Trials / Completed
CompletedNCT01843881
The Contribution of Incretin Hormones to Post-prandial Glucose Metabolism After Roux-en-Y Gastric Bypass
- Status
- Completed
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Adrian Vella · Academic / Other
- Sex
- All
- Age
- 20 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
The study is being undertaken to understand how the Roux-en-Y Gastric Bypass procedure can affect insulin secretion after meals. The hypothesis of this study is the Disposition Index is decreased in subjects who had previously undergone Roux-en-Y Gastric Bypass by glucagon-like peptide-1 (GLP-1) receptor blockade.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Exendin 9, 39 | Exendin 9,39 is a competitive antagonist of endogenous GLP-1. |
| DRUG | Placebo | A saline infusion will be given to match the study drug infusion. |
Timeline
- Start date
- 2012-03-01
- Primary completion
- 2013-09-01
- Completion
- 2013-12-01
- First posted
- 2013-05-01
- Last updated
- 2013-12-04
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01843881. Inclusion in this directory is not an endorsement.